Ibrutinib/rituximab: Lack of efficacy.

A man with refractory stage IVB mantle cell lymphoma exhibited lack of efficacy during treatment with rituximab and ibrutinib. Despite previous treatments and autologous stem cell transplant, his lymphoma continued to progress. He underwent CAR-T-cell therapies, which resulted in complications including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Post-treatment, he developed sclerosing cholangitis and his condition worsened, leading to a transition to comfort care. [Extracted from the article]